The Circulating Cell-free Genome Atlas Study

NCT ID: NCT02889978

Last Updated: 2023-09-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

15254 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-08-04

Study Completion Date

2024-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

GRAIL is using deep sequencing of circulating cell-free nucleic acids (cfNAs) to develop assays to detect cancer early in blood. The purpose of this study is to collect biological samples from participants with a new diagnosis of cancer (blood and tumor tissue) and from participants who do not have a diagnosis of cancer (blood) in order to characterize the population heterogeneity in cancer and non-cancer participants and to develop models for distinguishing cancer from non-cancer.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a prospective, multi-center, observational study with collection of de-identified biospecimens and clinical data from at least 15,000 participants from clinical networks in the United States and Canada. The study will enroll approximately 10,500 cancer participants (CANCER arm) and approximately 4,500 representative participants without a clinical diagnosis of cancer (NON-CANCER arm). Clinical information, demographics, and medical data relevant to cancer status are collected from all participants and their medical record at baseline (time of biospecimen collection), and subsequently from the medical record at intermittent future time points, at least annually for up to 5 years.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neoplasms Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cancer arm

Participants with new diagnosis of cancer (multiple tumor types) from which a blood sample and contemporaneous FFPE tumor tissue will be collected.

No interventions assigned to this group

Non-cancer arm

Participants with no known diagnosis or past history of cancer from which a blood sample will be collected.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 20 years or older
* Able to provide a written informed consent


* Age 20 years or older
* Able to provide a written informed consent

Have either of the following:

A. Confirmed cancer diagnosis (any stage I-IV, as well as carcinoma in situ (CIS) within 90 days prior to or up to 42 days after study blood draw, based upon assessment of a pathological specimen

OR

B. A high suspicion for a cancer diagnosis by clinical and/or radiological assessment, with planned biopsy or surgical resection to establish a definitive diagnosis within 6 weeks (42 days) after study blood draw

Exclusion Criteria

* Known current or prior diagnosis of cancer except non-melanoma skin cancer
* Oral or IV corticosteroid use in past 14 days prior to blood draw
* Pregnancy (by self-report)
* Current febrile illness
* Acute exacerbation or flare of an inflammatory condition requiring escalation in medical therapy within 14 days prior to blood draw.
* Recipient of organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant
* Poor health status or unfit to tolerate blood draw


* Known prior diagnosis of cancer except non-melanoma skin cancer
* Currently receiving, or ever received, any of the following therapies to treat their current cancer: surgical management of the cancer beyond that required to establish the cancer diagnosis; local, regional or systemic chemotherapy including chemoembolization; targeted therapy, immunotherapy including cancer vaccines; hormone therapy; or radiation therapy
* Pregnancy (by self-report)
* Current febrile illness
* Acute exacerbation or flare of an inflammatory condition requiring escalation in medical therapy within 14 days prior to blood draw.
* Recipient of organ transplant or prior non-autologous (allogeneic) bone marrow or stem cell transplant
* Poor health status or unfit to tolerate blood draw
Minimum Eligible Age

20 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

GRAIL, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Eric Fung, MD, PhD

Role: STUDY_DIRECTOR

GRAIL, Inc.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Southern Cancer Center, PC - Daphne

Daphne, Alabama, United States

Site Status

Southern Cancer Center, P.C. - Mobile Infirmary

Mobile, Alabama, United States

Site Status

Southern Cancer Center, PC - Mobile Airport

Mobile, Alabama, United States

Site Status

Southern Cancer Center, PC - Springhill Medical Center

Mobile, Alabama, United States

Site Status

Mayo Clinic - Arizona

Phoenix, Arizona, United States

Site Status

Mercy Fort Smith

Fort Smith, Arkansas, United States

Site Status

Sansum Clinic - 540

Santa Barbara, California, United States

Site Status

Sansum Clinic- 317

Santa Barbara, California, United States

Site Status

Sansum Clinic - Viborg

Solvang, California, United States

Site Status

Rocky Mountain Cancer Centers

Aurora, Colorado, United States

Site Status

Rocky Mountain Cancer Center

Boulder, Colorado, United States

Site Status

Rocky Mountain Cancer Centers

Centennial, Colorado, United States

Site Status

Rocky Mountain Cancer Center

Colorado Springs, Colorado, United States

Site Status

Rocky Mountain Cancer Centers

Denver, Colorado, United States

Site Status

Rocky Mountain Cancer Centers

Denver, Colorado, United States

Site Status

Rocky Mountain Cancer Centers

Englewood, Colorado, United States

Site Status

Rocky Mountain Cancer Center

Lakewood, Colorado, United States

Site Status

Rocky Mountain Cancer Centers

Littleton, Colorado, United States

Site Status

Rocky Mountain Cancer Centers

Lone Tree, Colorado, United States

Site Status

Rocky Mountain Cancer Centers

Longmont, Colorado, United States

Site Status

Rocky Mountain Cancer Center

Pueblo, Colorado, United States

Site Status

Rocky Mountain Cancer Centers

Thornton, Colorado, United States

Site Status

Hartford HealthCare Cancer Institute at Hartford Hospital

Hartford, Connecticut, United States

Site Status

Hartford New Britain

New Britain, Connecticut, United States

Site Status

UMHC Lennar Foundation - Coral Gables

Coral Gables, Florida, United States

Site Status

UMHC Sylvester- Coral Springs

Coral Springs, Florida, United States

Site Status

University of Miami Sylvester at Deerfield Beach

Deerfield Beach, Florida, United States

Site Status

University of Miami Sylvester at Hollywood

Hollywood, Florida, United States

Site Status

Mayo Clinic - Florida

Jacksonville, Florida, United States

Site Status

University of Miami Sylvester at Kendall

Kendall, Florida, United States

Site Status

University of Miami Sylvester Comprehensive Cancer Center

Miami, Florida, United States

Site Status

Florida Cancer Affiliates - Ocala

Ocala, Florida, United States

Site Status

Woodlands Medical Specialists, PA

Pensacola, Florida, United States

Site Status

University of Miami Sylvester at Plantation

Plantation, Florida, United States

Site Status

Illinois Cancer Specialists

Arlington Heights, Illinois, United States

Site Status

Illinois Cancer Specialists

Niles, Illinois, United States

Site Status

Baptist Health Lexington

Lexington, Kentucky, United States

Site Status

Baptist Health Louisville

Louisville, Kentucky, United States

Site Status

Baptist Health Paducah

Paducah, Kentucky, United States

Site Status

Maryland Oncology Hematology, P.A.

Bethesda, Maryland, United States

Site Status

Maryland Oncology Hematology, P.A.

Brandywine, Maryland, United States

Site Status

Maryland Oncology Hematology, P.A.

Clinton, Maryland, United States

Site Status

Maryland Oncology Hematology, P.A.

Columbia, Maryland, United States

Site Status

Maryland Oncology Hematology, P.A.

Rockville, Maryland, United States

Site Status

Maryland Oncology Hematology, P.A.

Silver Spring, Maryland, United States

Site Status

Dana-Farber Cancer Institute

Boston, Massachusetts, United States

Site Status

Lahey Hospital & Medical Center

Burlington, Massachusetts, United States

Site Status

Lahey Hospital & Medical Center - Peabody

Peabody, Massachusetts, United States

Site Status

Minnesota Oncology Hematology, P.A. - Main

Coon Rapids, Minnesota, United States

Site Status

Minnesota Oncology Hematology, P.A. - Edina

Edina, Minnesota, United States

Site Status

Minnesota Oncology Hematology, P.A. - Woodbury

Minneapolis, Minnesota, United States

Site Status

Mayo Clinic - Rochester

Rochester, Minnesota, United States

Site Status

Minnesota Oncology Hematology, P.A. - Coon Rapids

Woodbury, Minnesota, United States

Site Status

Mercy Joplin

Joplin, Missouri, United States

Site Status

Mercy Research - Springfield

Springfield, Missouri, United States

Site Status

Memorial Sloan Kettering - Basking Ridge

Basking Ridge, New Jersey, United States

Site Status

Memorial Sloan Kettering, NY - Monmouth

Middletown, New Jersey, United States

Site Status

New York Oncology Hematology, P.C.

Albany, New York, United States

Site Status

New York Oncology Hematology, P.C.

Albany, New York, United States

Site Status

Broome Oncology, LLC

Binghamton, New York, United States

Site Status

New York Oncology Hematology, P.C.

Clifton Park, New York, United States

Site Status

Broome Oncology, LLC

Johnson City, New York, United States

Site Status

Icahn School of Medicine at Mount Sinai

New York, New York, United States

Site Status

Memorial Sloan Kettering - Rockville Center

New York, New York, United States

Site Status

Memorial Sloan Kettering, NY - Commack

New York, New York, United States

Site Status

Memorial Sloan Kettering, NY - West Harrison

New York, New York, United States

Site Status

Memorial Sloan Kettering

New York, New York, United States

Site Status

Oncology Hematology Care, Inc. - Reading Road

Cincinnati, Ohio, United States

Site Status

Oncology Hematology Care, Inc. - Fairfield

Cincinnati, Ohio, United States

Site Status

Christ Hospital Health Network - The Lindner Center Cancer Research Division

Cincinnati, Ohio, United States

Site Status

Oncology Hematology Care, Inc. - Mercy Health

Cincinnati, Ohio, United States

Site Status

Oncology Hematology Care, Inc. - E. Galbraith

Cincinnati, Ohio, United States

Site Status

Oncology Hematology Care, Inc. - Malsbary

Cincinnati, Ohio, United States

Site Status

Cleveland Clinic

Cleveland, Ohio, United States

Site Status

Oncology Hematology Care, Inc. - Five Mile Road

Fairfield, Ohio, United States

Site Status

Oregon Health & Science University Knight Cancer Institute

Portland, Oregon, United States

Site Status

Northwest Cancer Specialists, P.C. dba Compass Oncology

Portland, Oregon, United States

Site Status

Northwest Cancer Specialists, P.C. dba Compass Oncology

Portland, Oregon, United States

Site Status

Northwest Cancer Specialists, P.C. dba Compass Oncology

Portland, Oregon, United States

Site Status

Northwest Cancer Specialists, P.C. dba Compass Oncology

Tualatin, Oregon, United States

Site Status

Lehigh Valley Hospital - Cedar Crest

Allentown, Pennsylvania, United States

Site Status

Cancer Center at Lehigh Valley Hospital - Muhlenberg

Bethlehem, Pennsylvania, United States

Site Status

Bon Secours Saint Francis Cancer Center

Greenville, South Carolina, United States

Site Status

Prisma Health - Upstate

Seneca, South Carolina, United States

Site Status

Spartanburg Regional Healthcare System

Spartanburg, South Carolina, United States

Site Status

Avera Research Institute

Sioux Falls, South Dakota, United States

Site Status

Tennessee Oncology Medical Park II

Chattanooga, Tennessee, United States

Site Status

Tennessee Oncology Memorial Plaza

Chattanooga, Tennessee, United States

Site Status

Tennessee Oncology Cleveland Clinic

Cleveland, Tennessee, United States

Site Status

Tennessee Oncology CMC

Crossville, Tennessee, United States

Site Status

Tennessee Oncology Dickson

Dickson, Tennessee, United States

Site Status

Tennessee Oncology Franklin

Franklin, Tennessee, United States

Site Status

Tennessee Oncology Gallatin

Gallatin, Tennessee, United States

Site Status

Tennessee Oncology Summit

Hermitage, Tennessee, United States

Site Status

Tennessee Oncology Lebanon

Lebanon, Tennessee, United States

Site Status

Tennessee Oncology Murfreesboro

Murfreesboro, Tennessee, United States

Site Status

Tennessee Oncology Midtown

Nashville, Tennessee, United States

Site Status

Tennessee Oncology Nashville

Nashville, Tennessee, United States

Site Status

Tennessee Oncology SCCBC

Nashville, Tennessee, United States

Site Status

Tennessee Oncology St. Thomas West

Nashville, Tennessee, United States

Site Status

Tennessee Oncology Skyline

Nashville, Tennessee, United States

Site Status

Tennessee Oncology Southern Hills

Nashville, Tennessee, United States

Site Status

Tennessee Oncology Shelbyville

Shelbyville, Tennessee, United States

Site Status

Tennessee Oncology Stonecrest

Smyrna, Tennessee, United States

Site Status

Texas Oncology - West Texas

Amarillo, Texas, United States

Site Status

Texas Oncology-Bedford

Bedford, Texas, United States

Site Status

TXO - Methodist Dallas Cancer Center

Dallas, Texas, United States

Site Status

Texas Oncology - Dallas Forest Ln

Dallas, Texas, United States

Site Status

Texas Oncology - Presbyterian Cancer Center Dallas

Dallas, Texas, United States

Site Status

Texas Oncology - Baylor Charles A. Sammons Cancer Center

Dallas, Texas, United States

Site Status

Texas Oncology-Fort Worth

Fort Worth, Texas, United States

Site Status

Texas Oncology-Southwest Fort Worth

Fort Worth, Texas, United States

Site Status

Texas Oncology - Grapevine

Grapevine, Texas, United States

Site Status

Texas Oncology Cancer Care and Research Center - Harlingen

Harlingen, Texas, United States

Site Status

Texas Oncology - Longview Cancer Center

Longview, Texas, United States

Site Status

Texas Oncology - McAllen

McAllen, Texas, United States

Site Status

Texas Oncology - Mesquite

Mesquite, Texas, United States

Site Status

Texas Oncology-New Braunfels

New Braunfels, Texas, United States

Site Status

Texas Oncology - Plano East

Plano, Texas, United States

Site Status

Texas Oncology - Plano West

Plano, Texas, United States

Site Status

Texas Oncology - Rockwall

Rockwall, Texas, United States

Site Status

Texas Oncology-San Antonio Downtown

San Antonio, Texas, United States

Site Status

Texas Oncology - San Antonio Northeast

San Antonio, Texas, United States

Site Status

Texas Oncology-San Antonio Medical Center

San Antonio, Texas, United States

Site Status

Texas Oncology-San Antonio Stone Oak

San Antonio, Texas, United States

Site Status

Texas Oncology - Sherman

Sherman, Texas, United States

Site Status

Texas Oncology-The Woodlands

The Woodlands, Texas, United States

Site Status

Texas Oncology - Tyler

Tyler, Texas, United States

Site Status

Texas Oncology - Weslaco

Weslaco, Texas, United States

Site Status

Texas Oncology - West Texas

Wichita Falls, Texas, United States

Site Status

Virginia Cancer Specialists, PC

Alexandria, Virginia, United States

Site Status

Virginia Cancer Specialists, PC

Arlington, Virginia, United States

Site Status

Virginia Cancer Specialists, PC

Fairfax, Virginia, United States

Site Status

Virginia Cancer Specialists, PC

Gainesville, Virginia, United States

Site Status

Virginia Cancer Specialists, PC

Leesburg, Virginia, United States

Site Status

Virginia Cancer Specialists, PC

Woodbridge, Virginia, United States

Site Status

Benaroya Research Institute at Virginia Mason

Seattle, Washington, United States

Site Status

Northwest Cancer Specialists, P.C. dba Compass Oncology

Vancouver, Washington, United States

Site Status

Yakima Valley Memorial Hospital/North Star Lodge

Yakima, Washington, United States

Site Status

UHN Princess Margaret Cancer Centre

Toronto, Ontario, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada

References

Explore related publications, articles, or registry entries linked to this study.

Mahal BA, Margolis M, Hubbell E, Chen C, Venstrom JM, Abran J, Kartlitz JJ, Wyatt AW, Klein EA. A Targeted Methylation-Based Multicancer Early Detection Blood Test Preferentially Detects High-Grade Prostate Cancer While Minimizing Overdiagnosis of Indolent Disease. JCO Precis Oncol. 2024 Aug;8:e2400269. doi: 10.1200/PO.24.00269.

Reference Type DERIVED
PMID: 39208374 (View on PubMed)

Bryce AH, Thiel DD, Seiden MV, Richards D, Luan Y, Coignet M, Zhang Q, Zhang N, Hubbell E, Kurtzman KN, Klein EA. Performance of a Cell-Free DNA-Based Multi-cancer Detection Test in Individuals Presenting With Symptoms Suspicious for Cancers. JCO Precis Oncol. 2023 Jul;7:e2200679. doi: 10.1200/PO.22.00679.

Reference Type DERIVED
PMID: 37467458 (View on PubMed)

Tang WHW, Yimer H, Tummala M, Shao S, Chung G, Clement J, Chu BC, Hubbell E, Kurtzman KN, Swanton C, Roberts LR. Performance of a targeted methylation-based multi-cancer early detection test by race and ethnicity. Prev Med. 2023 Feb;167:107384. doi: 10.1016/j.ypmed.2022.107384. Epub 2022 Dec 7.

Reference Type DERIVED
PMID: 36495927 (View on PubMed)

Shao SH, Allen B, Clement J, Chung G, Gao J, Hubbell E, Liu MC, Swanton C, Tang WHW, Yimer H, Tummala M. Multi-cancer early detection test sensitivity for cancers with and without current population-level screening options. Tumori. 2023 Jun;109(3):335-341. doi: 10.1177/03008916221133136. Epub 2022 Oct 31.

Reference Type DERIVED
PMID: 36316952 (View on PubMed)

Bredno J, Lipson J, Venn O, Aravanis AM, Jamshidi A. Clinical correlates of circulating cell-free DNA tumor fraction. PLoS One. 2021 Aug 25;16(8):e0256436. doi: 10.1371/journal.pone.0256436. eCollection 2021.

Reference Type DERIVED
PMID: 34432811 (View on PubMed)

Klein EA, Richards D, Cohn A, Tummala M, Lapham R, Cosgrove D, Chung G, Clement J, Gao J, Hunkapiller N, Jamshidi A, Kurtzman KN, Seiden MV, Swanton C, Liu MC. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. 2021 Sep;32(9):1167-1177. doi: 10.1016/j.annonc.2021.05.806. Epub 2021 Jun 24.

Reference Type DERIVED
PMID: 34176681 (View on PubMed)

Larson MH, Pan W, Kim HJ, Mauntz RE, Stuart SM, Pimentel M, Zhou Y, Knudsgaard P, Demas V, Aravanis AM, Jamshidi A. A comprehensive characterization of the cell-free transcriptome reveals tissue- and subtype-specific biomarkers for cancer detection. Nat Commun. 2021 Apr 21;12(1):2357. doi: 10.1038/s41467-021-22444-1.

Reference Type DERIVED
PMID: 33883548 (View on PubMed)

Liu MC, Oxnard GR, Klein EA, Swanton C, Seiden MV; CCGA Consortium. Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA. Ann Oncol. 2020 Jun;31(6):745-759. doi: 10.1016/j.annonc.2020.02.011. Epub 2020 Mar 30.

Reference Type DERIVED
PMID: 33506766 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

GRAIL-001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Genetic Analysis of Brain Tumors
NCT00031538 TERMINATED
The GalleriĀ® Community Research Program
NCT06603259 ENROLLING_BY_INVITATION